Fem-Dophilus^® contains two patented and clinically documented probiotic strains, Lacticaseibacillus rhamnosus GR-1^® and Limosilactobacillus reuteri RC-14^®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1^® and RC-14^® to colonize and promote healthy vaginal and urinary tract health. A special manufacturing process protects the probiotic strains in Fem-Dophilus^® from stomach acid and enhances probiotic bacterial survival to the lower intestine.